<DOC>
	<DOCNO>NCT01680198</DOCNO>
	<brief_summary>The primary aim study test hypothesis Paricalcitol , active form vitamin D , improve endothelial function stage 3-4 chronic kidney disease ( CKD ) patient . A secondary aim trial study relationship endothelial function plasma/serum genetic biomarkers bone mineral disorder CKD ( BMD-CKD ) renin angiotensin-aldosteron system ( RAS ) ( angiotensin II plasma renin activity ) .</brief_summary>
	<brief_title>Paricalcitol Endothelial Function Chronic Kidney Disease Patients ( PENNY Study )</brief_title>
	<detailed_description>Primary objective : Test hypothesis Paricalcitol , active form vitamin D improve endothelial function stage 3-4 chronic kidney disease ( CKD ) patient . Secondary analysis : Study relationship endothelial function plasma/serum genetic biomarkers bone mineral disorder CKD ( BMD-CKD ) renin angiotensin-aldosteron system ( RAS ) ( angiotensin II plasma renin activity ) . Background : Endothelial function alter patient CKD . Factors responsible disturbed endothelium-dependent vasodilatation CKD include reduce bioactivity nitric oxide ( NO ) pathway decrease endothelial NO synthase ( NOS ) activity inhibition via accumulation endogenous inhibitor . In patient CKD dialysis serum 25 ( OH ) D3 1,25 ( OH ) 2D3 level associate FMD . Vitamin D receptor 1 -hydroxylase activity present endothelial vascular smooth muscle cell 1,25 ( OH ) 2D3 stimulates vascular endothelial growth factor prostacyclin production vascular smooth muscle cell . These biological observation may clinical implication paricalcitol treatment predicts longer survival ESRD patient recent data link vitamin D progression ESRD patient stage 3-5 CKD . Furthermore , previous study u show BMSI polymorphism vitamin D receptor gene associate LVH LVH progression ESRD patient . Study population : Patients stage 3-4 CKD sex age range 18-80 year . Patients take vitamin D supplement , abnormal liver function test , symptomatic cardiovascular disease , diabetes cancer whose medication change study exclude . Design Methods : The study double-blind , randomize , parallel group trial . After baseline measurement , patient iPTH level &gt; 65 pg/ml ; Ca 8.4- 10.00 mg/dL P 2.9-4.5 randomize receive 2 microgram Paricalcitol capsule ( match placebo ) daily , 12 week . This dose adjust base clinical laboratory parameter maximum dose 2 microgram daily . During study subject experience suppression serum iPTH ( define serum iPTH &lt; 15 pg/mL ) , hypercalcemia ( define Ca &gt; 11.0 mg/dL ) , subject continue take study drug reduce dosage 1 mcg day return 2 week unscheduled visit . If value unscheduled visit serum iPTH and/or Ca return &gt; 15 pg/mL and/or &lt; 11.0 mg/dL , respectively , drug discontinue . Flow mediate vasodilatation measure accord validate protocol develop coordinate center national ( Italian ) work group vascular function test . Primary end-point : Change Flow Mediated Dilatation ( FMD ) induce Paricalcitol comparison Placebo . Study power : To detect 2 % difference ( standard deviation : ± 3.0 % ) change FMD Paracalcitol treat untreated patient power 80 % , confidence level use two-tailed test 5 % potential attrition rate 15 % , least 44 patient per group require ( 88 patient total ) . Statistical analysis : Data summarize mean ± standard deviation ( normally distribute data ) , median inter-quartile range ( non normally distribute data ) percent frequency , comparison group make independent T-Test , Mann-Whitney Test , Chi Square test , appropriate . Within patient comparison do statistical test pair observation . Data analysis primary outcome perform compare change FMD Paracalcitol treat untreated patient use T-Test independent observation . Possible difference risk factor baseline control randomization ( i.e . difference due chance ) account use multivariate regression analysis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<criteria>Patients iPTH level &gt; 65 pg/ml ; Ca 8.4 10.00 mg/dL P 2.94.5 Negative serum pregnancy test female subject childbering potential . Informed consent . Use vitamin D supplement . Altered liver function test ( bilirubin , aminotransferases total alkaline phosphatase &gt; 3 time upper limit normal range ) . Sympthomatic cardiovascular disease basis clinical history . Cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Paracalcitol</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Endothelial dysfunction</keyword>
	<keyword>Flow mediate vasodilation</keyword>
</DOC>